FDA Approves Dendreon’s drug
By Seattle Business Magazine April 29, 2010
Dendreon’s prostate cancer treatment Provenge won much-coveted approval from the U.S. Food and Drug Association today. The company’s stock (Nasdaq: DNDN) is up 15 percent after the mid-day announcement.
Dendreon’s prostate cancer treatment Provenge won much-coveted approval from the U.S. Food and Drug Association today. The company’s stock (Nasdaq: DNDN) is up 15 percent after the mid-day announcement.